Success Metrics

Clinical Success Rate
94.8%

Based on 55 completed trials

Completion Rate
95%(55/58)
Active Trials
76(46%)
Results Posted
27%(15 trials)
Terminated
3(2%)

Phase Distribution

Ph phase_1
60
36%
Ph phase_2
79
47%
Ph early_phase_1
12
7%
Ph phase_3
6
4%
Ph not_applicable
8
5%

Phase Distribution

72

Early Stage

79

Mid Stage

6

Late Stage

Phase Distribution165 total trials
Early Phase 1First-in-human
12(7.3%)
Phase 1Safety & dosage
60(36.4%)
Phase 2Efficacy & side effects
79(47.9%)
Phase 3Large-scale testing
6(3.6%)
N/ANon-phased studies
8(4.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

79.7%

55 of 69 finished

Non-Completion Rate

20.3%

14 ended early

Currently Active

76

trials recruiting

Total Trials

167

all time

Status Distribution
Active(90)
Completed(55)
Terminated(14)
Other(8)

Detailed Status

Recruiting58
Completed55
Active, not recruiting18
Not yet recruiting13
Withdrawn11
unknown8

Development Timeline

Analytics

Development Status

Total Trials
167
Active
76
Success Rate
94.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 112 (7.3%)
Phase 160 (36.4%)
Phase 279 (47.9%)
Phase 36 (3.6%)
N/A8 (4.8%)

Trials by Status

active_not_recruiting1811%
completed5533%
withdrawn117%
unknown85%
not_yet_recruiting138%
enrolling_by_invitation11%
recruiting5835%
terminated32%

Recent Activity

Clinical Trials (167)

Showing 20 of 167 trialsScroll for more
NCT06801041Phase 2

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Recruiting
NCT06200155Phase 2

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Recruiting
NCT05546658Early Phase 1

Effects of Psilocybin in Obsessive Compulsive Disorder

Active Not Recruiting
NCT07506395Phase 1

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

Not Yet Recruiting
NCT07499583Phase 1

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

Not Yet Recruiting
NCT06072898Phase 2

A Randomized Neuroimaging Trial of Psilocybin in Depression

Recruiting
NCT07216404Phase 2

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

Recruiting
NCT07296094Phase 2

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

Not Yet Recruiting
NCT06299319Phase 1

Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

Recruiting
NCT05416229Phase 2

Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

Completed
NCT07336238Phase 2

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

Recruiting
NCT06731621Phase 1

Psilocybin for Treatment-Resistant Depression in Autism

Recruiting
NCT07211438Phase 2

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

Not Yet Recruiting
NCT06660381Phase 1

Psilocybin-assisted Treatment for Cannabis Use Disorder

Recruiting
NCT04123314Early Phase 1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Recruiting
NCT04620759Phase 2

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

Active Not Recruiting
NCT05068791Early Phase 1

Psilocybin-facilitated Treatment for Chronic Pain

Recruiting
NCT06442423Phase 1

Open-Label Psilocybin Study in Transdiagnostic Population

Recruiting
NCT05227742Early Phase 1

Exploratory Study of Low Dose Psilocybin

Withdrawn
NCT07169747Phase 2

Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
167